Latest / Glaucoma, Vision & Longevity: Supplements & Science / Can Damaged Optic Nerve Cells Be Made Young Again? The First Human Glaucoma Reprogramming Trial Has Begun

Transcript

Can Damaged Optic Nerve Cells Be Made Young Again? The First Human Glaucoma Reprogramming Trial Has Begun · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Can damaged optic nerve cells be made young again?
• 0:03
  SPEAKER_00: The first human glaucoma reprogramming trial has begun.
• 0:07
  SPEAKER_00: As of August 28, 2026, the first human trial of partial epigenetic reprogramming is underway.
• 0:13
  SPEAKER_00: Life Biosciences Experimental Therapy, ER 100, is being tested in adults with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.
• 0:24
  SPEAKER_00: The first participant was dosed on June 9, 2026, after the United States Food and Drug Administration cleared the investigational new drug application in January.
• 0:34
  SPEAKER_00: The treatment is not a stem cell transplant.
• 0:36
  SPEAKER_00: It does not replace the optic nerve with new tissue.
• 0:40
  SPEAKER_00: Instead, it attempts to make surviving retinal ganglion cells behave more like younger cells by temporarily activating three powerful gene-regulating proteins, OCT4, SOX-2, and KLF-4, collectively called OSK.
• 0:54
  SPEAKER_00: The central question is extraordinary but precise.
• 0:57
  SPEAKER_00: Can an old or injured retinal ganglion cell recover enough of its youthful function to preserve or perhaps partially restore vision?
• 1:06
  SPEAKER_00: The answer is not yet known.
• 1:08
  SPEAKER_00: Animal studies provide a credible biological rationale, including improvements in retinal ganglion cell activity, optic nerve axon measurements, DNA methylation patterns, and visual behavior.
• 1:19
  SPEAKER_00: But the human trial is small, primarily designed to test safety, and has not yet produced publicly reported efficacy results.
• 1:27
  SPEAKER_00: The short answer: fact in mice, OA expression has restored aspects of youthful DNA methylation and gene expression patterns, increased retinal ganglion cell survival after optic nerve injury, promoted optic nerve axon regeneration after an experimental crush injury, improved pattern electroretinogram signals, improved visually guided behavior in a mouse glaucoma model, produced prolonged visual improvement after glaucoma-like damage.
• 1:54
  SPEAKER_00: Show no obvious retinal tumors or gross retinal structural abnormalities in long-term mouse studies.
• 2:00
  SPEAKER_00: In non-human primates, company reported studies of a non-arteritic anterior ischemic optic neuropathy-like injury found improved retinal ganglion cell electrical activity and increased axon density measurements after treatment.
• 2:15
  SPEAKER_00: These findings have been presented by Life Biosciences and described in a patent, but the most detailed non-human primate data have not yet appeared as a fully independent peer-reviewed clinical efficacy publication.
• 2:28
  SPEAKER_00: Inference ER-100 is biologically more likely to help surviving but dysfunctional retinal ganglion cells than to replace cells that have already died.
• 2:38
  SPEAKER_00: It may also help some damaged axons resume function or grow over limited distances.
• 2:44
  SPEAKER_00: However, there is currently no direct evidence that ER-100 can rebuild a completely lost human optic nerve, restore all missing retinal ganglion cells, or correctly reconnect new axons with the visual centers of the brain.
• 2:57
  SPEAKER_00: Prediction.
• 2:59
  SPEAKER_00: The most realistic early success would be evidence that the therapy reaches retinal ganglion cells.
• 3:05
  SPEAKER_00: No unacceptable inflammation, pressure elevation, retinal damage, or uncontrolled cellular reprogramming.
• 3:12
  SPEAKER_00: A reproducible improvement in retinal electrical activity or visual field performance in a subset of patients.
• 3:18
  SPEAKER_00: A dramatic restoration of advanced glaucoma vision is possible in theory, but remains unlikely based on the present evidence.
• 3:26
  SPEAKER_00: What is ER100?
• 3:29
  SPEAKER_00: ER100 is an intravitreal gene therapy.
• 3:32
  SPEAKER_00: A modified adenassociated viral vector is injected into the vitreous cavity of one eye.
• 3:37
  SPEAKER_00: The vector carries genetic instructions for producing OCT4, SOX-2, KLF4, and a molecular switch that allows the treatment to be activated by oral doxycycline.
• 3:48
  SPEAKER_00: Participants take doxycycline for 56 days.
• 3:51
  SPEAKER_00: Doxycycline does not act as a conventional glaucoma drug.
• 3:55
  SPEAKER_00: Its purpose in this system is to activate the genetic cassette that produces OSK in cells transduced by the vector.
• 4:02
  SPEAKER_00: The therapy is intended to deliver OSK primarily to retinal ganglion cells, the neurons whose axons form the optic nerve.
• 4:09
  SPEAKER_00: ER100 is not designed to edit the patient's existing genes in the way that a gene editing treatment would.
• 4:17
  SPEAKER_00: Instead, it adds extra genetic instructions that may remain in cells without permanently changing the original genome.
• 4:25
  SPEAKER_00: That distinction is important, but it does not make the treatment risk-free.
• 4:29
  SPEAKER_00: Extra genetic material can still produce unwanted effects, and adenoassociated viral vectors can trigger inflammation, immune responses, or rare vector-related complications.
• 4:40
  SPEAKER_00: Why OCT4, SOX2, and KLF-4?
• 4:43
  SPEAKER_00: OCT4, SOX2, and KLF4 are transcription factors.
• 4:48
  SPEAKER_00: They do not simply turn one gene on or off.
• 4:50
  SPEAKER_00: They bind DNA and influence large networks of genes involved in cell identity, chromatin structure, development responses, and cellular repair.
• 4:58
  SPEAKER_00: The original four-factor reprogramming cocktail also includes CMIC, which can help convert adult cells into induced pluripotent stem cells.
• 5:06
  SPEAKER_00: However, CMIC is strongly associated with cell growth and cancer biology.
• 5:12
  SPEAKER_00: ER100 omits CMIC.
• 5:14
  SPEAKER_00: OCT-4 OCT4 is a central regulator of cellular plasticity and developmental gene networks.
• 5:20
  SPEAKER_00: In full cellular reprogramming, it helps push a mature cell toward a pluripotent state.
• 5:25
  SPEAKER_00: In partial reprogramming, the goal is not to push the cell all the way back to an embryonic state.
• 5:30
  SPEAKER_00: Instead, a brief or controlled amount of OCT4 may help loosen age-associated regulatory patterns and make older chromatin more accessible to remodeling.
• 5:41
  SPEAKER_00: SOX-2 works with OCT4 and other factors to reorganize gene regulatory networks.
• 5:47
  SPEAKER_00: It is important in maintaining neural and stem cell programs.
• 5:51
  SPEAKER_00: In a retinal ganglion cell, controlled SOX-2 activity could theoretically help reopen developmental programs related to axon growth, synaptic maintenance, and neuronal resilience.
• 6:02
  SPEAKER_00: KLF4.
• 6:03
  SPEAKER_00: KLF4 regulates chromatin accessibility, cell differentiation, stress responses, and cellular identity.
• 6:10
  SPEAKER_00: It can help remodel the structure around DNA, allowing some previously silenced genes to become active.
• 6:16
  SPEAKER_00: KLF-4 is also part of the reason careful dosing is essential.
• 6:20
  SPEAKER_00: It participates in both differentiation and cellular reprogramming, so excessive or prolonged expression could disturb the mature retinal ganglion cell state.
• 6:29
  SPEAKER_00: Why the cell does not necessarily become a stem cell?
• 6:32
  SPEAKER_00: Full reprogramming requires strong and sustained activation of several factors, followed by major changes in cell identity and the acquisition of pluripotency.
• 6:41
  SPEAKER_00: Partial reprogramming attempts to stop the process earlier.
• 6:45
  SPEAKER_00: The proposed sequence is OSK enters the retinal ganglion cell.
• 6:49
  SPEAKER_00: OSK binds regulatory regions across the genome.
• 6:53
  SPEAKER_00: Age-associated chromatin and DNA methylation patterns begin to change.
• 6:58
  SPEAKER_00: Gene networks involved in neuronal maintenance and axon growth become more youthful.
• 7:02
  SPEAKER_00: OSK expression is stopped before the cell crosses into a pluripotent state.
• 7:07
  SPEAKER_00: The cell remains a retinal ganglion cell, but operates in a more resilient, growth competent state.
• 7:13
  SPEAKER_00: This separation between rejuvenation and pluripotency is the central safety hypothesis.
• 7:19
  SPEAKER_00: It is supported by mouse experiments showing no increase in retinal ganglion cell proliferation and no obvious loss of retinal structure.
• 7:28
  SPEAKER_00: However, partial does not mean perfectly controlled, particularly in humans with different vector distribution, genetics, disease severity, and immune responses.
• 7:38
  SPEAKER_00: What does epigenetic age mean?
• 7:41
  SPEAKER_00: Cells can remain genetically similar while changing how their genes are used.
• 7:45
  SPEAKER_00: This regulation is called epigenetics.
• 7:48
  SPEAKER_00: Important epigenetic mechanisms include DNA methylation, in which chemical groups attach to DNA and influence gene activity, histone modification, which affects how tightly DNA is packaged, chromatin organization, regulatory proteins that determine which genes are accessible, noncoding RNA and other gene regulating systems.
• 8:08
  SPEAKER_00: With age, these patterns become less precise.
• 8:11
  SPEAKER_00: Some genes become abnormally silenced while others become abnormally active.
• 8:16
  SPEAKER_00: This accumulation of regulatory noise may contribute to inflammation, impaired energy production, weaker stress responses, and reduced regenerative ability.
• 8:26
  SPEAKER_00: DNA methylation clocks estimate biological age by examining methylation at selected sites across the genome.
• 8:33
  SPEAKER_00: These clocks are useful biomarkers, but they are not equivalent to a complete measurement of aging.
• 8:38
  SPEAKER_00: Reversing a methylation clock does not automatically prove that every harmful feature of aging has been repaired.
• 8:45
  SPEAKER_00: A 2024 review specifically cautioned that epigenetic clock reversal and true functional rejuvenation should not be treated as identical concepts.
• 8:56
  SPEAKER_00: The strongest evidence that methylation changes may be functionally important comes from the original mouse study.
• 9:02
  SPEAKER_00: Injury accelerated the methylation age signature of retinal ganglion cells.
• 9:07
  SPEAKER_00: OSK reversed this signature and suppression of the DNA demethylating enzymes TET1 and TET II blocked much of the improvement in axon regeneration and visual function.
• 9:18
  SPEAKER_00: That does not prove that methylation is the only cause of glaucoma.
• 9:22
  SPEAKER_00: It suggests that at least some age and injury-associated methylation changes participate in the loss of neuronal function.
• 9:30
  SPEAKER_00: The scientific path to ER100.
• 9:32
  SPEAKER_00: Early partial reprogramming studies.
• 9:35
  SPEAKER_00: Earlier animal studies showed that temporary activation of reprogramming factors could reverse some age-associated traits in mice without producing the full effects of induced pluripotency.
• 9:46
  SPEAKER_00: Cyclic exposure to reprogramming factors improved several molecular and physiological measures in progyroid and normal mice.
• 9:53
  SPEAKER_00: These studies established the broader concept that age-associated cellular decline might be partly reversible rather than entirely caused by irreversible damage.
• 10:03
  SPEAKER_00: The landmark 2020 retinal study, the pivotal study, was published in Nature in 2020.
• 10:09
  SPEAKER_00: Researchers delivered OSK to retinal ganglion cells using an inducible viral system.
• 10:15
  SPEAKER_00: They studied three related situations: optic nerve crush injury, experimental glaucoma caused by elevated eye pressure, normal aging.
• 10:24
  SPEAKER_00: In the optic nerve crush model, OSK increased the number of labeled axons growing beyond the injury site.
• 10:30
  SPEAKER_00: The treatment also improved survival of retinal ganglion cells.
• 10:34
  SPEAKER_00: In the mouse glaucoma model, treatment began after elevated eye pressure had already caused measurable damage.
• 10:41
  SPEAKER_00: OSK treated eyes showed increased optic nerve axon density, improved pattern electroretinogram responses, improved optimotor visual acuity.
• 10:51
  SPEAKER_00: No evidence that the improvement was caused by retinal ganglion cell proliferation.
• 10:55
  SPEAKER_00: The treated mice recovered approximately half of the visual acuity lost after the glaucoma-like injury.
• 11:01
  SPEAKER_00: In older mice, OSK also restored a large proportion of age-altered retinal ganglion cell gene expression toward a younger pattern.
• 11:10
  SPEAKER_00: Long-term mouse follow-up.
• 11:12
  SPEAKER_00: A later study examined whether the effect would last.
• 11:15
  SPEAKER_00: In mice with experimentally induced glaucoma, two months of OSK expression restored visual behavior to approximately healthy levels.
• 11:23
  SPEAKER_00: With continued expression, the improvement remained near healthy levels for approximately 11 months.
• 11:29
  SPEAKER_00: When doxycycline was removed and OSK expression was switched off, visual improvement gradually declined but did not immediately disappear.
• 11:38
  SPEAKER_00: The researchers reported no obvious retinal tumors or major changes in retinal thickness after up to 21 months of continuous or cyclic treatment.
• 11:47
  SPEAKER_00: This is encouraging for two reasons.
• 11:50
  SPEAKER_00: The benefit was not merely an immediate electrical artifact.
• 11:53
  SPEAKER_00: The apparent safety signal lasted much longer than the treatment period.
• 11:57
  SPEAKER_00: But mouse longevity studies cannot exclude rare human cancer or retinal risks.
• 12:03
  SPEAKER_00: A study involving a few dozen mice cannot reliably detect a complication that might occur once in several hundred or several thousand treated people.
• 12:12
  SPEAKER_00: How strong is the evidence for each claimed effect?
• 12:15
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 12:20
  SPEAKER_00: Did ER100 rescue dying neurons or regenerate lost structures?
• 12:26
  SPEAKER_00: This is one of the most important distinctions.
• 12:28
  SPEAKER_00: What the studies support.
• 12:30
  SPEAKER_00: The animal studies are consistent with several mechanisms: rescue of stressed but living retinal ganglion cells, restoration of electrical activity in dysfunctional neurons, preservation of axons that would otherwise have degenerated, regrowth of some axon segments from surviving neurons, improved transport and maintenance within retinal ganglion cells, reversal of some age-associated gene expression abnormalities.
• 12:56
  SPEAKER_00: The absence of retinal ganglion cell proliferation is important.
• 12:59
  SPEAKER_00: The treatment did not appear to work by creating a new population of retinal ganglion cells.
• 13:05
  SPEAKER_00: It worked by changing the state of cells that were still present.
• 13:09
  SPEAKER_00: What the studies do not prove, they do not prove that O replaced retinal ganglion cells that had already died, rebuilt an entire optic nerve after complete destruction, restored retinal ganglion cell synapses that had permanently disappeared, reconnected regenerated axons to the correct brain targets, repaired visual cortex changes caused by long-standing glaucoma, reversed severe end-stage visual field loss.
• 13:36
  SPEAKER_00: In the mouse glaucoma model, the claim that axon density returned to a non-glaucomatous level is striking.
• 13:42
  SPEAKER_00: But axon density restoration can represent a mixture of true regrowth, axon preservation, recovery of axonal transport, improved labeling, or repair of partially damaged fibers.
• 13:53
  SPEAKER_00: The experiment did not demonstrate that newly grown fibers traveled the full distance to the brain and formed correct functional synapses.
• 14:01
  SPEAKER_00: Why glaucoma is a difficult test?
• 14:03
  SPEAKER_00: Glaucoma is not simply a condition in which eye pressure kills retinal ganglion cells immediately.
• 14:09
  SPEAKER_00: Damage can involve dendritic and synaptic dysfunction, abnormal axonal transport, injury at the optic nerve head, degeneration of axons, retinal ganglion cell death, degeneration of terminals in the brain, changes in the visual pathways and visual cortex.
• 14:27
  SPEAKER_00: Some of these stages may be reversible, others are not.
• 14:31
  SPEAKER_00: This creates a therapeutic window.
• 14:33
  SPEAKER_00: A patient with moderate glaucoma may have many retinal ganglion cells that are alive but electrically impaired or metabolically stressed.
• 14:41
  SPEAKER_00: A patient with advanced glaucoma may have lost most of the cells and axons needed to carry information to the brain.
• 14:48
  SPEAKER_00: Therefore, the most plausible initial use of partial reprogramming is not restore all lost vision.
• 14:55
  SPEAKER_00: It is make the remaining retinal ganglion cells more functional and more resistant while possibly encouraging limited repair of damaged axons.
• 15:04
  SPEAKER_00: The challenge of optic nerve regeneration is that axons must grow through the nerve, cross the optic chiasm, reach appropriate targets, become myelinated, and form correctly organized connections.
• 15:16
  SPEAKER_00: Researchers have emphasized that retinotopically correct reconnection with brain targets remains a major barrier for regenerative treatments.
• 15:24
  SPEAKER_00: What the ER-100 Human Trial is actually testing.
• 15:28
  SPEAKER_00: The current study is NCT 17244, a first-in-human phase 1 trial sponsored by Life Biosciences.
• 15:36
  SPEAKER_00: Trial population.
• 15:38
  SPEAKER_00: The registry describes up to 18 participants, 12 adults with open-angle glaucoma, 6 adults with non-arteritic anterior ischemic optic neuropathy.
• 15:48
  SPEAKER_00: The glaucoma portion is the dose escalation stage.
• 15:52
  SPEAKER_00: The non-arteritic anterior ischemic optic neuropathy portion is described as a dose expansion stage.
• 15:58
  SPEAKER_00: Public patient-facing descriptions indicate that the glaucoma participants have moderate to advanced disease, while the non-arteritic anterior ischemic optic neuropathy group represents recent optic nerve ischemic injury.
• 16:11
  SPEAKER_00: A program patent describes age thresholds of approximately 35 years or older for glaucoma and 50 years or older for non-arteritic anterior ischemic optic neuropathy.
• 16:23
  SPEAKER_00: The final registry criteria should be treated as the controlling source for enrollment.
• 16:27
  SPEAKER_00: Roten treatment schedule.
• 16:29
  SPEAKER_00: Participants receive one intravitreal injection, treatment in one eye only, oral doxycycline for 56 days, long-term follow-up for up to five years.
• 16:40
  SPEAKER_00: The public registry lists a low-dose open-angle glaucoma cohort receiving two 1010 vector genomes per eye.
• 16:47
  SPEAKER_00: The first participant at a dose level is monitored as a sentinel participant, after which an independent safety monitoring board reviews the results before additional dosing or escalation.
• 16:58
  SPEAKER_00: The publicly visible summary does not clearly disclose every planned dose level.
• 17:04
  SPEAKER_00: A patent describing the program gives additional technical information, including a dual vector adeno-associated virus type 2 system and a one-to-one mixture of the vector carrying the OSK cassette with the vector carrying the doxycycline responsive activator.
• 17:21
  SPEAKER_00: Because a patent may describe alternative or illustrative embodiments, it should not be assumed to be identical to the final clinical protocol.
• 17:30
  SPEAKER_00: Primary safety objectives: the main purpose of phase one is safety and tolerability, not proof of vision restoration.
• 17:36
  SPEAKER_00: The primary safety measures include treatment emergent adverse events, dose limiting toxicities, eye examination findings, intraocular pressure, retinal and optic nerve structure, blood and laboratory testing, liver function testing, immune responses, possible vector shedding or biodistribution.
• 17:55
  SPEAKER_00: The important early safety windows include the doxycycline treatment period and the period after doxycycline has stopped, exploratory efficacy measures.
• 18:05
  SPEAKER_00: The study also examines best corrected visual acuity, Humphrey automated visual field testing, contrast sensitivity, pattern electroretinogram, full field electroretinogram, optical coherence tomography of the retinal nerve fiber layer, optical coherence tomography of the ganglion cell layer, fundus photography, and optic nerve appearance, patient reported quality of life.
• 18:29
  SPEAKER_00: These measures are valuable, but this small, open-label phase one trial cannot reliably prove that ER100 improves vision.
• 18:37
  SPEAKER_00: There is no large untreated control group, and glaucoma visual fields can fluctuate substantially.
• 18:43
  SPEAKER_00: In non-arteritic anterior ischemic optic neuropathy, some spontaneous visual recovery occurs even without treatment, making a controlled comparison particularly important.
• 18:54
  SPEAKER_00: Follow-up.
• 18:56
  SPEAKER_00: The registry describes approximately 15 clinic visits, with frequent assessments during the first six months and annual visits through year five.
• 19:05
  SPEAKER_00: The long follow-up is necessary because the treatment introduces persistent genetic instructions into retinal cells, and because cancer, inflammation, delayed retinal degeneration, or late immune effects may not appear during the first few weeks.
• 19:19
  SPEAKER_00: What would count as a genuine human biological effect?
• 19:23
  SPEAKER_00: A weak result would be an isolated improvement in one visual test.
• 19:27
  SPEAKER_00: That could result from learning effects, measurement variability, regression toward the average, or natural fluctuation.
• 19:34
  SPEAKER_00: A more convincing result would show several findings moving together.
• 19:38
  SPEAKER_00: Dose-related target engagement, improved pattern lectroretinogram beyond test-retest variability, improvement in visual field locations that were previously abnormal, better contrast sensitivity or visual acuity, concordant retinal ganglion cellar retinal nerve fiber layer findings, persistence after doxycycline has stopped, noun-explained retinal swelling or inflammatory artifact, a similar pattern across more than one participant, better outcomes than expected from natural history.
• 20:06
  SPEAKER_00: Evidence that improvement occurs in the treated eye.
• 20:08
  SPEAKER_00: Rather than equally in both eyes for glaucoma, the strongest evidence would be a sustained improvement in reproducible visual field locations.
• 20:17
  SPEAKER_00: For non-arteritic anterior ischemic optic neuropathy, the strongest early evidence would be recovery that exceeds the expected spontaneous recovery pattern in comparable patients.
• 20:28
  SPEAKER_00: ER-100 compared with ASP2767 and other neuroprotective approaches.
• 20:34
  SPEAKER_00: ASP767, ASP2767 is another investigational intravitreal treatment being studied in glaucoma-related optic nerve damage.
• 20:43
  SPEAKER_00: Its public program includes a phase 1 dose escalation component, a phase 2 dose expansion component, low and high dose groups, a sham injection comparator in phase 2, visual field and structural endpoints, immune response monitoring.
• 20:58
  SPEAKER_00: The Estellus public trial information does not provide enough publicly validated mechanistic detail to make a precise molecular comparison with OSK.
• 21:07
  SPEAKER_00: Its phase 2 sham controlled design may ultimately offer a cleaner test of efficacy than the current ER-100 phase 1 study, although the treatments are not being tested head-to-head.
• 21:22
  SPEAKER_00: Several other approaches attempt to protect retinal ganglion cells, pressure lowering, which reduces one major cause of ongoing damage, bromonidine, and other medicines that may increase neurotrophic signaling.
• 21:34
  SPEAKER_00: Nicotinamide, which aims to support retinal energy metabolism, aceticoline and related metabolic compounds, neurotrophic factors, mitochondrial support, modulation of inflammation, mammalian target of rapamycin, and phosphatase intensin homologue pathways, electrical stimulation, cell replacement, and stem cell derived retinal ganglion cells.
• 21:56
  SPEAKER_00: Some have encouraging animal or early human findings, but no.
• 22:00
  SPEAKER_00: No broadly accepted treatment has yet demonstrated reliable restoration of lost glaucomatous visual fields independent of eye pressure control.
• 22:08
  SPEAKER_00: Evidence for several neuroprotective compounds remains suggestive rather than definitive.
• 22:14
  SPEAKER_00: Why epigenetic reprogramming could be different?
• 22:17
  SPEAKER_00: Conventional neuroprotection generally attempts to keep a damaged neuron alive by reducing stress, improving energy production, limiting excitotoxicity, or increasing survival signals.
• 22:29
  SPEAKER_00: OSK could theoretically do more.
• 22:31
  SPEAKER_00: It may simultaneously influence axon growth competence, synaptic maintenance, stress responses, mitochondrial function, neuronal gene expression, chromatin organization, DNA methylation, resistance to age-associated degeneration.
• 22:47
  SPEAKER_00: That is the theoretical advantage, not merely protecting an old retinal ganglion cell, but changing the cellular state that makes it old and vulnerable.
• 22:54
  SPEAKER_00: The disadvantage is that a broad regulatory reset is less precise than a conventional drug.
• 23:00
  SPEAKER_00: It may affect many genes that are not directly involved in glaucoma and could create new risks.
• 23:05
  SPEAKER_00: Major risks and uncertainties.
• 23:08
  SPEAKER_00: Uncontrolled reprogramming.
• 23:10
  SPEAKER_00: The treatment must stay in a narrow zone.
• 23:12
  SPEAKER_00: Too little OSK may do nothing.
• 23:15
  SPEAKER_00: Enough OSK may improve function.
• 23:17
  SPEAKER_00: Too much or too long may alter cell identity or promote abnormal growth.
• 23:21
  SPEAKER_00: Adeno-associated viral vectors can persist in cells, so stopping doxycycline may reduce expression without removing the vector itself.
• 23:29
  SPEAKER_00: Tumor formation.
• 23:31
  SPEAKER_00: Full reprogramming with the four-factor cocktail can produce pluripotent cells and teratomas.
• 23:37
  SPEAKER_00: Premature or incomplete reprogramming has also been associated with abnormal epigenetic states and cancer in animal models.
• 23:44
  SPEAKER_00: Omitting C my C and targeting postmitotic retinal ganglion cells may reduce the risk, but it does not eliminate it.
• 23:52
  SPEAKER_00: The long-term mouse data are reassuring but not conclusive.
• 23:56
  SPEAKER_00: Human safety monitoring will need to continue for years.
• 24:00
  SPEAKER_00: Loss of retinal ganglion cell identity.
• 24:03
  SPEAKER_00: Partial reprogramming may temporarily suppress some mature cell identity programs, even if the cell does not become pluripotent.
• 24:11
  SPEAKER_00: A retinal ganglion cell that loses too much of its specialized identity could become less capable of processing or transmitting visual signals.
• 24:19
  SPEAKER_00: Inflammation, intravitrial adeno-associated viral therapy, exposes the vector to immune cells in the vitreous and retina.
• 24:26
  SPEAKER_00: Ocular inflammation, uveitis, retinal vasculitis, increased eye pressure, and reduced retinal function are established concerns in ocular gene therapy.
• 24:37
  SPEAKER_00: A recent systematic review found that intravitrial delivery has higher rates of inflammatory complications than subretinal delivery in the published ocular gene therapy literature.
• 24:47
  SPEAKER_00: Preexisting antibodies can also reduce vector delivery and make treatment of the second eye more difficult.
• 24:54
  SPEAKER_00: Unwanted expression in other retinal cells.
• 24:57
  SPEAKER_00: Intravitrial adenoassociated virus type 2 can reach retinal ganglion cells, but it may also reach other retinal cell types.
• 25:04
  SPEAKER_00: Expression in amacrels, miller cells, or other cells could contribute to benefits, side effects, or unpredictable results.
• 25:12
  SPEAKER_00: Correct reconnection with the brain.
• 25:14
  SPEAKER_00: Even if a retinal ganglion cell grows a new axon, that axon must travel through the optic nerve, cross the optic chiasm appropriately, reach the correct visual relay, form a useful synapse, become properly myelinated, preserve the spatial map of vision.
• 25:30
  SPEAKER_00: ER100 has not demonstrated this complete sequence in humans or non-human primates.
• 25:36
  SPEAKER_00: The limits of DNA methylation clocks.
• 25:38
  SPEAKER_00: A younger DNA methylation score is encouraging but not definitive.
• 25:42
  SPEAKER_00: A clock may change without restoring every component of cellular health.
• 25:47
  SPEAKER_00: Partial reprogramming may improve some age-associated pathways while leaving telomere shortening, accumulated mutations, extracellular matrix damage, vascular disease, or chronic inflammation unresolved.
• 26:00
  SPEAKER_00: Biological estimates for what ER-100 might achieve.
• 26:04
  SPEAKER_00: These are subjective scientific forecasts, not trial results or statistical predictions.
• 26:09
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 26:13
  SPEAKER_00: The probability of a safety signal is not the same as the probability of a therapeutic benefit.
• 26:19
  SPEAKER_00: For example, immune activation or vector shedding would demonstrate that the treatment is biologically active, but would not mean that it is helping vision.
• 26:29
  SPEAKER_00: Earliest realistic timeline.
• 26:31
  SPEAKER_00: The trial began administratively on March 2nd, 2026, and the first participant was publicly reported as dosed on June 9, 2026.
• 26:40
  SPEAKER_00: The registry estimates primary completion in May 2027 and overall study completion in March 2032.
• 26:47
  SPEAKER_00: A realistic timeline is late 2027 to 2028.
• 26:52
  SPEAKER_00: Preliminary human safety and possible retinal function signals.
• 26:56
  SPEAKER_00: 2029 to 2031.
• 26:59
  SPEAKER_00: More credible efficacy data from a controlled phase 2 study if phase 1 is acceptable.
• 27:04
  SPEAKER_00: 2031 to 2034.
• 27:07
  SPEAKER_00: Potential late stage trials assessing visual field preservation or restoration.
• 27:11
  SPEAKER_00: 2034 to 2038.
• 27:14
  SPEAKER_00: Earliest plausible clinical availability if efficacy, manufacturing, immune safety, and long-term tumor surveillance are successful.
• 27:22
  SPEAKER_00: Clinical availability before 2033 would require unusually strong phase 1 and phase 2 results, rapid enrollment, an efficient regulatory pathway, and no major safety concerns.
• 27:34
  SPEAKER_00: A later timeline is more likely.
• 27:36
  SPEAKER_00: Could this actually restore lost vision?
• 27:39
  SPEAKER_00: The strongest case for Rosynth, the scientific case, is stronger than ordinary speculation.
• 27:44
  SPEAKER_00: First, retinal ganglion cells are accessible from inside the eye.
• 27:49
  SPEAKER_00: A single local injection can potentially deliver treatment to the relevant neurons without exposing the entire body to reprogramming factors.
• 27:57
  SPEAKER_00: Second, the 2020 mouse study did not merely show a younger DNA methylation pattern.
• 28:03
  SPEAKER_00: It also showed improved retinal ganglion cell activity, axon regeneration after injury, and improved visual behavior after glaucoma-like damage.
• 28:12
  SPEAKER_00: The benefit occurred after damage had already taken place and without evidence of new retinal ganglion cell proliferation.
• 28:19
  SPEAKER_00: Third, prolonged mouse follow-up found that visual improvement could last for many months and that long-term retinal toxicity was not obvious.
• 28:28
  SPEAKER_00: Fourth, Life Biosciences reports that a related approach improved pattern electroretinogram responses and axon density measurements in a non-human primate ischemic optic neuropathy model.
• 28:40
  SPEAKER_00: That is important because primate retinas, visual pathways, and retinal ganglion cell distributions are more similar to humans than those of mice.
• 28:50
  SPEAKER_00: Together, these findings make it biologically plausible that some visual loss comes from dysfunctional, aged, or injured cells that are not yet irreversibly dead.
• 28:59
  SPEAKER_00: The strongest case against tanks the animal studies do not show replacement of dead retinal ganglion cells.
• 29:06
  SPEAKER_00: They do not show complete restoration of the human optic nerve.
• 29:10
  SPEAKER_00: They do not show that regenerated axons reconnect correctly with the brain.
• 29:15
  SPEAKER_00: The human trial is also small, open label, and primarily a safety study.
• 29:20
  SPEAKER_00: Any apparent visual improvement could be difficult to distinguish from test variability, natural recovery, or changes unrelated to reprogramming.
• 29:29
  SPEAKER_00: The treatment may work best in a narrow group.
• 29:32
  SPEAKER_00: The disease is not too advanced.
• 29:34
  SPEAKER_00: A substantial number of retinal ganglion cells remain alive.
• 29:37
  SPEAKER_00: Axons are damaged, but not completely destroyed.
• 29:41
  SPEAKER_00: The brain's visual targets remain sufficiently intact.
• 29:44
  SPEAKER_00: The vector reaches enough retinal ganglion cells.
• 29:47
  SPEAKER_00: Inflammation is controlled.
• 29:49
  SPEAKER_00: OSK expression stays within the safe partial reprogramming range.
• 29:54
  SPEAKER_00: That is not the same as reversing blindness caused by widespread neuronal loss.
• 29:58
  SPEAKER_00: What would constitute a real breakthrough?
• 30:01
  SPEAKER_00: The current trial would represent a genuine breakthrough if it showed all or most of the following.
• 30:07
  SPEAKER_00: No serious dose-related inflammation or retinal toxicity.
• 30:11
  SPEAKER_00: No evidence of uncontrolled reprogramming or tumor formation.
• 30:15
  SPEAKER_00: A reproducible improvement in pattern electroretinogram activity.
• 30:19
  SPEAKER_00: Improvement in visual acuity or contrast sensitivity that exceeds test variability.
• 30:24
  SPEAKER_00: Improvement in repeatable visual field locations.
• 30:27
  SPEAKER_00: Especially in glaucoma, concordant retinal nerve fiber layer or ganglion cell measurements.
• 30:32
  SPEAKER_00: A dose-response relationship.
• 30:35
  SPEAKER_00: Benefits lasting after doxycycline has stopped.
• 30:38
  SPEAKER_00: Effects that are clearly greater than expected.
• 30:40
  SPEAKER_00: Natural recovery in non-arteritic anterior ischemic optic neuropathy.
• 30:45
  SPEAKER_00: Confirmation in a larger, randomized, controlled study.
• 30:48
  SPEAKER_00: The most important first success would not be a dramatic cure.
• 30:52
  SPEAKER_00: It would be proof that human retinal ganglion cells can safely enter a younger, more functional state without losing their identity.
• 31:00
  SPEAKER_00: If that is demonstrated, partial epigenetic reprogramming could become a new category of regenerative treatment.
• 31:08
  SPEAKER_00: It might eventually be combined with pressure lowering, metabolic support, neurotrophic therapies, or methods that guide axons back to the brain.
• 31:16
  SPEAKER_00: Conclusion ER100 is neither a proven anti-aging therapy nor a stem cell replacement treatment.
• 31:23
  SPEAKER_00: It is a high-risk, highly experimental attempt to reset some age and injury associated gene regulatory patterns inside surviving retinal ganglion cells.
• 31:32
  SPEAKER_00: The strongest evidence supports functional rejuvenation and limited repair of surviving neurons, not replacement of dead cells.
• 31:40
  SPEAKER_00: The mouse data are unusually compelling, the non-human primate data are encouraging but less independently documented, and the first human trial is now testing whether the concept is safe enough to pursue.
• 31:54
  SPEAKER_00: For patients, the practical message is straightforward.
• 31:58
  SPEAKER_00: ER100 is not clinically available and it should not replace eye pressure treatment or regular glaucoma monitoring.
• 32:05
  SPEAKER_00: But scientifically, the trial marks an important boundary.
• 32:08
  SPEAKER_00: For the first time, partial cellular reprogramming is being tested directly in people with a disease caused by neuronal aging and degeneration.
• 32:17
  SPEAKER_00: The possibility of restoring some lost vision is real, but it remains a hypothesis that only carefully controlled human trials can confirm.
• 32:26
  SPEAKER_00: Selected sources, Liu and colleagues, reprogramming to recover youthful epigenetic information and restore vision, nature carg and colleagues, sustained vision recovery by OSK Gene Therapy in a mouse model of glaucoma.
• 32:40
  SPEAKER_00: Clinicaltrials.gov study, NCD 729244, ER 100 in glaucoma and non-arteritic anterior chemicoptic neuropathy.
• 32:49
  SPEAKER_00: Life Biosciences Announcement of First Participant Dosing.
• 32:52
  SPEAKER_00: Life Biosciences Announcement of United States Food and Drug Administration Clearance.
• 32:56
  SPEAKER_00: Life Biosciences non-human primate presented at the American Academy of Ophthalmology.
• 33:00
  SPEAKER_00: Life Biosciences non-human primated data presented at the Association for Research in Vision and Ophthalmology.
• 33:06
  SPEAKER_00: Systematic Review of Ocular Adeno-associated Virus Gene Therapy Safety.
• 33:12
  SPEAKER_00: The Challenge of Regenerative Therapies for the Optic Nerve and Glaucoma, A Stellus AS767 Glaucoma Study.
• 33:18
  SPEAKER_00: All links to sources are available in the text version of this article.
• 33:22
  SPEAKER_00: You can find the full article at VisualFieldTest.com.
• 33:25
  SPEAKER_00: Thanks for listening.
• 33:27
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.